Antimicrobial and immunuregulatory functions of lactoferrin and its potential therapeutic application

Journal of Endotoxin Research

Volumn 8, Issue 6, 2002, Pages 403-417

  Caccavo, Domenico ^a   Pellegrino, Nelly M ^a   Altamura, Maria ^a   Rigon, Amelia ^b   Amati, Luigi ^c   Amoroso, Antonio ^d   Jirillo, Emilio ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CD14 ANTIGEN; CORTICOSTEROID; ENDOTOXIN; INTERLEUKIN 1; INTERLEUKIN 2; IRON BINDING PROTEIN; LACTOFERRIN; LIPID A; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; TETRACYCLINE; TUMOR NECROSIS FACTOR ALPHA; EPITOPE;

ANTIMICROBIAL ACTIVITY; ARTHRITIS; BACTERIAL MEMBRANE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BINDING AFFINITY; CELL INTERACTION; CYTOTOXICITY; GASTRITIS; GRAM NEGATIVE BACTERIUM; IMMUNOREGULATION; MACROPHAGE; MOUSE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN SECRETION; REVIEW; SEPTIC SHOCK; URINARY TRACT INFECTION; DRUG EFFECT; HUMAN; IMMUNOLOGY; METABOLISM; MICROBIOLOGICAL EXAMINATION; MONOCYTE; SECRETION;

ANIMALIA; BACTERIA (MICROORGANISMS); NEGIBACTERIA;

ANTIBODIES, MONOCLONAL; EPITOPES; GRAM-NEGATIVE BACTERIA; HUMANS; INTERLEUKIN-1; KILLER CELLS, NATURAL; LACTOFERRIN; LIPOPOLYSACCHARIDES; MICROBIAL SENSITIVITY TESTS; MONOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036948412     PISSN: 09680519     EISSN: None     Source Type: Journal    
DOI: 10.1179/096805102125001000     Document Type: Review

References (160)

1. Sánchez L, Calvo M, Brock JH. Biological role of lactoferrin. Arch Dis Child 1992; 67: 657-661.
2. Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica 1995; 80: 252-267.
3. Cramer E, Pryzwansky KB, Villeval JL, Testa U, Brenton-Gorius J. Ultrastructural localization of lactoferrin and myeloperoxidase in human neutrophils by immunogold. Blood 1985; 65: 423-432.
4. Anderson BF, Baker HM, Norris GE, Rice DW, Baker EN. Structure of human lactoferrin: crystallographic structure analysis and refinement at 2.8 Å resolution. J Mol Biol 1989; 209: 711-734.
5. Aisen P, Leibman A. Lactoferrin and transferrin: a comparative study. Biochim Biophys Acta 1972; 257: 314-323.
6. Moguilevsky N, Retegui LA, Masson PL. Comparison of human lactoferrins from milk and neutrophilic leukocytes. Relative molecular mass, isoelectric point, iron-binding properties and uptake by the liver. Biochem J 1985; 229: 353-359.
7. Derisbourg P, Wieruszeski JM, Montreuil J, Spik G. Primary structure of glycans isolated from human leukocyte lactotransferrin. Absence of fucose residues questions the proposed mechanism of hyposideraemia. Biochem J 1990; 269: 821-825.
8. Masson PL, Heremans JF. Lactoferrin in milk from different species. Comp Biochem Physiol B 1971; 39: 119-129.
9. Mathur NB, Dwarkadas AM, Sharma VK, Saha K, Jain N. Anti-infective factors in preterm human colostrum. Acta Paediatr Scand 1990; 79: 1039-1044.
10. Hennart PF, Brasseur DJ, Delogne Desnoeck JB, Dramaix MM, Robyn CE. Lysozyme, lactoferrin and secretory immunoglobulin A content in breast milk: influence of duration of lactation, nutrition status and parity of mother. Am J Clin Nutr 1991; 53: 32-39.
11. Kijlstra A, Jeurissen SH, Koning KM. Lactoferrin levels in normal human tears. Br J Ophthalmol 1983; 67: 199-202.
12. Tauber PF, Zaneveld LJD, Propping D, Schumacher GFB. Components of human split ejaculates. I. Spermatozoa, fructose, immunoglobulins, albumin, lactoferrin, transferrin and other plasma proteins. J Reprod Fertil 1975; 43: 249-267.
13. Hansen NE, Malmquist J, Thorell J. Plasma myeloperoxidase and lactoferrin measured by radioimmunoassay: relations to neutrophil kinetics. Acta Med Scand 1975; 198: 437-443.
14. Olofsson T, Olsson I, Venge P, Elgefors B. Serum myeloperoxidase and lactoferrin in neutropenia. Scand J Haematol 1977; 18: 73-80.
15. Birgens HS. The biological significance of lactoferrin in haematology. Scand J Haematol 1984; 33: 22-30.
16. Bagby GC. Regulation of granulopoiesis: the lactoferrin controversy. Blood Cells 1989; 15: 386-399.
17. Bennet RM, Mohla CT. A solid phase radio-inummoassay for the measurement of lactoferrin in human plasma: variations with age, sex and disease. J Lab Clin 1976; 88: 156-166.
18. Antonsen S, Wiggers P, Dalhoj J, Blaabjerg O. An enzyme linked immunosorbent assay for plasma-lactoferrin. Concentrations in 362 healthy adult blood donors. Scand J Clin Lab Invest 1993; 53:133-144.
19. Sykes JAC, Thomas MJ, Goldie DJ, Turner GM. Plasma lactoferrin levels in pregnancy and cystic fibrosis. Clin Chem Acta 1982; 122: 385-393.
20. Rosenmund A, Friedi J, Bebie H, Straub PW. Plasma lactoferrin/neutrophil ratio. A re-assessment of normal values and of the clinical relevance. Acta Haematol 1988; 80: 40-48.
21. Cohen MS, Britigan BE, French M, Bean K. Preliminary observations on lactoferrin secretion in human vaginal mucus: variation during the menstrual cycle, evidence of hormonal regulation, and implication for infection with Neisseria gonorrhoeae. Am J Obstet Gynecol 1987; 157: 1122-1125.
22. Pentecost BT, Teng CT. Lactotransferrin is the major estrogen inducible protein of mouse uterine secretions. J Biol Chem 1987; 262: 10134-10139.
23. Shigeta H, Newbold RR, McLachlan JA, Teng C. Estrogenic effect on the expression of estrogen receptor, COUP-TF, and lactoferrin mRNA in developing mouse tissues. Mol Reprod Dev 1996; 45: 21-30.
24. Teng CT, Yang N. Estrogen regulation of human lactoferrin gene activity. In: Hutchens TW, Lönnerdal B. (eds) Lactoferrin: Interactions and Biological Functions. Totowa, NJ: Humana, 1997; 135-153.
25. Yang N, Shigeta H, Shi H, Teng CT. Estrogen-related receptor, hERR1, modulates estrogen receptor-mediated response of human lactoferrin gene promoter. J Biol Chem 1996; 271: 5795-5804.
26. Zhang Z, Teng CT. Estrogen receptor-related receptor α1 interacts with co-activator and constitutively activates the estrogen response elements of the human lactoferrin gene. J Biol Chem 2000; 275: 20837-20846.
27. Teng CT, Gladwell W, Beard C, Walmer D, Teng CS, Brenner R. Lactoferrin gene expression is estrogen responsive in human and rhesus monkey endometrium. Mol Hum Reprod 2002; 8: 58-67.
28. Hu WL, Regoeczi E, Chindemi PA, Bolyos M. Lactoferrin interferes with uptake of iron from transferrin and asialotransferrin by the rat liver. Am J Physiol 1993; 264: G112-G117.
29. Van Snick JL, Masson PL, Heremans JF. The involvement of lactoferrin in the hyposideremia of acute inflammation. J Exp Med 1974;140: 1068-1084.
30. Bennet RM, Kokocinski T. Lactoferrin turnover in man. Clin Sci 1979; 57: 453-460.
31. Van Snick JL, Masson PL. The binding of human lactoferrin to mouse peritoneal cells. J Exp Med 1976; 144: 1568-1580.
32. Birgens HS, Karle H, Hansen NE, Kristensen LO. Lactoferrin receptors in normal and leukaemic human blood cells. Scand J Haematol 1984; 33: 275-280.
33. Mazurier J, Legrand D, Hu WL, Montreuil J, Spik G. Expression of human lactotransferrin receptors in phytohemagglutinin-stimulated human peripheral blood lymphocytes. Isolation of the receptors by antiligand-affinity chromatography. Eur J Biochem 1989; 179: 481-487.
34. Rochard E, Legrand D, Mazurier J, Montreuil J, Spik G. The N-terminal domain I of human lactotransferrin binds specifically to phytohemagglutinin-stimulated peripheral blood human lymphocyte receptors. FEBS Lett 1989; 255: 201-204.
35. Bi BY, Leveugle B, Liu JL et al. Immunolocalization of the lactotransferrin receptor on the human T lymphoblastic cell line Jurkat. Eur J Cell Biol 1994; 65: 164-171.
36. Bi BY, Liu JL, Legrand D et al. Internalization of human lactoferrin by the Jurkat human lymphoblastic T-cell line. Eur J Cell Biol 1996; 69: 288-296.
37. Kawasaki Y, Sato K, Shinmoto H, Dosako S. Role of basic residues of human lactoferrin in the interaction with B lymphocytes. Biosci Biotechnol Biochem 2000; 64: 314-318.
38. Birgens HS, Hansen NE, Karle H, Kristensen LO. Receptor binding of lactoferrin by human monocytes. Br J Haematol 1983; 54: 383-391.
39. Ismail M, Brock JH. Binding of lactoferrin and transferring to the human promonocytic cell line U937. Effect on iron uptake and release. J Biol Chem 1993; 268: 21618-21625.
40. Eda S, Kikugawa K, Beppu M. Binding characteristics of human lactoferrin to the human monocytic leukaemia cell line THP-1 differentiated into macrophages. Biol Pharm Bull 1996; 19: 167-175.
41. Eda S, Beppu M, Yokoyama N, Kikugawa K. Novel lectin-like proteins on the surface of human monocytic leukaemia cell line THP-1 cells that recognize oxidized cells. Arch Biochem Biophys 2001; 385: 186-193.
42. Leveugle B, Mazurier J, Legrand D, Mazurier C, Montreuil J, Spik G. Lactotransferrin binding to its platelet receptor inhibits platelet aggregation. Eur J Biochem 1993; 213: 1205-1211.
43. Nillesse N, Pierce A, Lecoq M, Benaissa M, Spik G. Expression of the lactotransferrin receptor during the differentiation process of the megakaryocyte Dami cell line. Biol Cell 1994; 82: 149-159.
44. Bennatt DJ, Ling YY, McAbee DD. Isolated rat hepatocytes bind lactotransferrins by the RHL-1 subunit of the asialoglycoprotein receptor in a galactose-independent manner. Biochemistry 1997; 36: 8367-8376.
45. McAbee DD, Jiang X, Walsh KB. Lactoferrin binding to the rat asialoglycoprotein receptor requires the receptor's lectin properties. Biochem J 2000; 348: 113-117.
46. Huettinger M, Retzek H, Eder M, Goldenberg H. Characteristics of chylomicron remnant uptake into rat liver. Clin Biochem 1988; 21: 87-92.
47. van Dijk MC, Ziere GJ, Boers W, Linthorst C, Bijsterbosch MK, van Berkel TJ. Recognition of chylomicron remnants and betamigrating very-low-density lipoproteins by the remnant receptor of parenchymal liver cells is distinct from the liver alpha 2-macroglobulin-recognition site. Biochem J 1991; 279: 863-870.
48. Ziere GJ, Bijsterbosch MK, van Berkel TJC. Removal of 14 N-terminal amino acids of lactoferrin enhances its affinity for parenchymal liver cells and potentiates the inhibition of β-very low density lipoprotein binding. J Biol Chem 1993; 268: 27069-27075.
49. 2-macroglobulin receptor and transport to endosomes. FEBS Lett 1995; 360: 70-74.
50. Davidson LA, Lönnerdal B. Specific binding of lactoferrin to brush-border membrane: ontogeny and effect of glycan chain. Am J Physiol 1988; 254: G580-G585.
51. Gislason J, Iyer S, Hutchens TW, Lönnerdal B. Lactoferrin receptors in piglet small intestine: lactoferrin binding properties, ontogeny, and regional distribution in the gastrointestinal tract. J Nutr Biochem 1993; 4: 528-533.
52. Hu WL, Mazurier J, Montreuil J, Spik G. Isolation and partial characterization of a lactotransferrin receptor from mouse intestinal brush-border. Biochemistry 1990; 29: 535-541.
53. Mazurier J, Montreuil J, Spik G. Visualization of lactotransferrin brush-border receptors by ligand-blotting. Biochim Biophys Acta 1985; 821: 453-460.
54. Kawakami H, Lönnerdal B. Isolation and function of a receptor for human lactoferrin in human fetal intestinal brush-border membranes. Am J Physiol 1991; 261: G841-G846.
55. El Yazidi-Belkoura I, Legrand D, Nuijens J, Slomianny MC, van Berkel P, Spik G. The binding of lactoferrin to glycosaminoglycans on enterocyte-like HT29-18-C1 cells is mediated through basic residues located in the N-terminus. Biochim Biophys Acta 2001; 1568; 197-204.
56. Suzuki YA, Shin K, Lönnerdal B. Molecular cloning and functional expression of a human intestinal lactoferrin receptor. Biochemistry 2001; 40: 15771-15779.
57. Mikogami T, Marianne T, Spik G. Effect of intracellular iron depletion by picolinic acid on expression of the lactoferrin receptor in the human colon carcinoma cell subclone HT29-18-C1. Biochem J 1995; 308: 391-397.
58. Legrand D, Mazurier J, Maes P, Rochard E, Montreuil J, Spik G. Inhibition of the specific binding of human lactotransferrin to human peripheral-blood phytohaemagglutinin-stimulated lymphocytes by fluorescein labelling and location of the binding site. Biochem J 1991; 276: 733-738.
59. Peen E, Johansson A, Engquist M, Skogh T. Hepatic and extrahepatic clearance of circulating human lactoferrin: an experimental study in rat. Eur J Haematol 1998; 61: 151-159.
60. Masson PL, Heremans JF, Prignot JJ, Wauters G. Immunohistochemical localization and bacteriostatic properties of an iron-binding protein from bronchial mucus. Thorax 1966; 21: 538-544.
61. Oram JD, Reiter B. Inhibition of bacteria by lactoferrin and other iron chelating agents. Biochim Biophys Acta 1968; 170: 351-365.
62. Reiter B, Oram JD. Bacterial inhibitors in milk and other biological fluids. Nature 1967; 216: 328-330.
63. Rainard P. Bacteriostasis of Escherichia coli by bovine lactoferrin, transferrin and immunoglobulins (IgG1, IgG2, IgM) acting alone or in combinations. Vet Microbiol 1986; 11: 103-115.
64. Reiter B, Brock JH, Steel ED. Inhibition of Escherichia coli by bovine colostrum and post-colostral milk. II. The bacteriostatic effect of lactoferrin on a serum susceptible and serum-resistant strain of E. coli. Immunology 1975; 28: 83-95.
65. Spik G, Cheron A, Montreuil J, Dolby JM. Bacteriostasis of a milk-sensitive strains of Escherichia coli by immunoglobulins and iron-binding proteins in association. Immunology 1978; 35: 663-671.
66. Stephens S, Dolby JM, Montreuil J, Spik G. Differences in inhibition of the growth of commensal and enteropathogenic strains of Escherichia coli by lactotransferrin and secretory immunoglobulin A isolated from human milk. Immunology 1980; 41: 597-603.
67. Griffiths E, Humphreys J. Bacteriostatic effect of human milk and bovine colostrum on Escherichia coli: importance of bicarbonate. Infect Immun 1977; 15: 396-401.
68. Rainard P. Bacteriostatic activity of bovine milk lactoferrin against mastitic, bacteria. Vet Microbiol 1986; 11: 387-392.
69. Leitch EC, Willcox MD. Synergic antistaphylococcal properties of lactoferrin and lysozyme. J Med Microbiol 1998; 47: 837-842.
70. Masson PL, Heremans JF. Metal-combining properties of human lactoferrin (red milk protein). I. The involvement of bicarbonate in the reaction. Eur J Biochem 1968; 6: 579-584.
71. Arnold RR, Russel JE, Champion WJ, Brewer M, Gauthier JJ. Bactericidal activity of human lactoferrin: differentiation from the stasis of iron deprivation. Infect Immun 1982; 35: 792-799.
72. Arnold RR, Russel JE, Champion WJ, Gauthier JJ. Bactericidal activity of human lactoferrin: influence of physical conditions and metabolic state of the target microorganism. Infect Immun 1981; 32: 655-660.
73. Mickelsen PA, Blackman E, Sparling FP. Ability of Neisseria gonorrhoeae, Neisseria meningitidis, and commensal Neisseria species to obtain iron from lactoferrin. Infect Immun 1982; 35: 915-920.
74. Schryvers AB, Morris LJ. Identification and characterization of the human lactoferrin-binding protein from Neisseria meningitidis. Infect Immun 1988; 56: 1144-1149.
75. Schryvers AB. Identification of the transferring- and lactoferrin-binding proteins in Haemophilus influenzae. J Med Microbiol 1989; 29: 121-130.
76. Du RP, Wang Q, Yang YP et al. Cloning and expression of the Moraxella catarrhalis lactoferrin receptor genes. Infect Immun 1998; 66: 3656-3665.
77. Peterson KM, Alderete JF. Iron uptake and increased intracellular enzyme activity follow host lactoferrin binding by Trichomonas vaginalis receptors. J Exp Med 1984; 160: 398-410.
78. Wilson ME, Vorhies RW, Andersen KA, Britigan BE. Acquisition of iron from transferring and lactoferrin by the protozoan Leishmania chagasi. Infect Immun 1994; 62: 3262-3269.
79. Arnold RR, Cole MF, McGhee JR. A bactericidal role for human lactoferrin. Science 1977; 197: 263-265.
80. Ellison III RT, Giehl TJ, LaForce FM. Damage of the outer membrane of enteric Gram-negative bacteria by lactoferrin and transferrin Infect Immun 1988; 56: 2774-2781.
81. Ellison III RT, Giehl TJ. Killing of Gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest 1991; 88: 1080-1091.
82. Appelmelk BJ, An Y-Q, Geerts M et al. Lactoferrin is a lipid A-binding protein. Infect Immun 1994; 62: 2628-2632.
83. Caccavo D, Afeltra A, Pece S et al. Lactoferrin-lipid A-lipopolysaccharide interaction: inhibition by anti-human lactoferrin monoclonal antibody AGM 10.14. Infect Immun 1999; 67: 4668-4672.
84. Naidu SS, Svensson U, Kishore AR, Satynarayan Naidu A. Relationship between antibacterial activity and porin binding of lactoferrin in Escherichia coli and Salmonella typhimurium. Antimicrob Agents Chemother 1993; 37: 240-245.
85. Elass-Rochard E, Rosenau A, Legrand D et al. Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli O55:B5 lipopolysaccharide. Biochem J 1995; 312: 839-845.
86. van Berkel PHC, Geerts MEJ, van Veen HA et al. Glycosylated and unglycosylated human lactoferrins both bind iron and show identical affinities towards human lysozyme and bacterial lipopolysaccharide, but differ in their susceptibilities towards tryptic proteolysis. Biochem J 1995; 312: 107-114.
87. 5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. Biochem J 1997; 328: 145-151.
88. Brandenburg K, Jurgens G, Muller M, Fukuoka S, Koch MH. Biophysical characterization of lipopolysaccharide and lipid A inactivation by lactoferrin. J Biol Chem 2001; 382: 1215-1225.
89. Bellamy W, Takase M, Yamauchi K, Wakabayashi H, Kawase K, Tomita M. Identification of the bactericidal domain of lactoferrin. Biochim Biophys Acta 1992; 1121: 130-136.
90. Odell EW, Sarra R, Foxworthy M, Chapple DS, Evans RW. Antibacterial activity of peptides to a loop region in human lactoferrin. FEBS Lett 1996; 382: 175-178.
91. Ulvatne H, Haukland HH, Olsvik Ø, Vorland LH. Lactoferricin B causes depolarisation of the cytoplasmic membrane of Escherichia coli ATCC 25922 and fusion of negatively charged liposomes. FEBS Lett 2001; 492: 62-65.
92. Zhang G-H, Mann DM, Tsai C-M. Neutralization of endotoxin in vitro and in vivo by a human lactoferrin-derived peptide. Infect Immun 1999; 67: 1353-1358.
93. Kirkpatrick CH, Green I, Rich RR, Schade AL. Inhibition of growth of Candida albicans by iron-unsaturated lactoferrin: relation to host-defense mechanisms in chronic mucocutaneous candidiasis J Infect Dis 1971; 124: 539-544.
94. Cassone A. Cell wall of Candida albicans, its functions and its impact on the host. Curr Top Med Mycol 1989; 3: 249-314.
95. Torosantucci A, Palma C, Boccanera M, Ausiello CM, Spagnoli GC, Cassone A. Lymphoproliferative and cytotoxic responses of human peripheral blood mononuclear cells to mannoprotein constituents of Candida albicans. J Gen Microbiol 1990; 136: 2155-2163.
96. Palma C, Serbousek D, Torosantucci A, Cassone A, Djeu JY. Identification of a mannoprotein fraction from Candida albicans that enhances human polymorphonuclear leukocyte (PMNL) functions and stimulates lactoferrin in PMNL inhibition of candidal growth. J Infect Dis 1992; 166: 1103-1112.
97. Bellamy W, Wakabayashi H, Takase M, Kawase K, Shimamura S, Tomita M. Killing of Candida albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med Microbiol Immunol 1993; 182: 97-105.
98. Kuipers ME, de Vries HG, Eikelboom MC, Meijer DK, Swart PJ. Synergistic fungistatic effects of lactoferrin in combination with antifungal drugs against clinical Candida isolates. Antimicrob Agents Chemother 1999; 43: 2635-2641.
99. Harmsen MC, Swart PJ, de Bethumne MP et al. Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis 1995; 172: 380-388.
100. Marchetti M, Longhi C, Conte MP, Pisani S, Valenti P, Seganti L. Lactoferrin inhibits herpes simplex virus type 1 adsorption to Vero cells. Antiviral Res 1996; 29: 221-231.
101. Grover M, Giouzeppos O, Schnagl RD, May JT. Effect of human milk prostaglandins and lactoferrin on respiratory syncytial virus and rotavirus. Acia Pediatr 1997; 86: 315-316.
102. Superti F, Ammendolia MG, Valenti P, Seganti L. Antirotaviral activity of milk proteins: lactoferrin prevents rotavirus infection in the enterocyte-like cell line HT-29. Med Microbiol Immunol 1997; 186: 83-91.
103. Yi, M, Kaneko S, Yu DY, Murakarni S. Hepatitis C virus envelope proteins bind lactoferrin. J Virol 1997; 71: 5997-6002.
104. Swart PJ, Kuipers EM, Smit C, Van Der Strate BW, Harmsen MC, Meijer DK. Lactoferrin. Antiviral activity of lactoferrin. Adv Exp Med Biol 1998; 443: 205-213.
105. Ikeda M, Sugiyama K, Tanaka T et al. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. Biochem Biophys Res Commun 1998; 245: 549-553.
106. Ikeda M, Nozaki A, Sugiyama K et al. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res 2000; 66: 51-63.
107. Portelli J, Gordon A, May JT. Effect of compounds with antibacterial activities in human milk on respiratory syncytial virus and cytomegalovirus in vitro. J Med Microbiol 1998; 47: 1015-1018.
108. Hasegawa K, Motsuchi W, Tanaka S, Dosako S. Inhibition with lactoferrin of in vitro infection with human herpes virus. Jpn J Med Sci Biol 1994; 47: 73-85.
109. Defer MC, Dugas B, Picard O, Damais C. Impairment of circulating lactoferrin in HIV-1 infection. Cell Mol Biol 1995; 41: 417-421.
110. Duncan RL, McArthur WP. Lactoferrin-mediated modulation of mononuclear cell activities. I. Suppression of the murine in vitro primary antibody responses. Cell Immunol 1981; 63: 308-320.
111. - murine thymocytes. Immunol Lett 1991; 30: 119-123.
112. Dhennin-Duthille I, Masson M, Damiens E, Fillebeen C, Spik G, Mazurier J. Lactoferrin upregulates the expression of CD4 antigen through the stimulation of the mitogen-activated protein kinase in the human lymphoblastic T Jurkat cell line. J Cell Biochem 2000; 79: 583-593.
113. Nishiya K, Horwitz DA. Contrasting effects of lactoferrin on human lymphocyte and monocyte natural killer activity and antibody-dependent cell-mediated cytotoxicity. J Immunol 1982; 129: 2519-2523.
114. McCormick JA, Markey GM, Morris TC. Lactoferrin-inducible monocyte cytotoxicity for K562 cells and decay natural killer lymphocyte cytotoxicity. Clin Exp Immunol 1991; 83: 154-156.
115. Horwitz DA, Bakke AC, Abo W, Nishiya K. Monocyte and NK cell cytotoxic activity in human adherent cell preparations: discriminating effects of interferon and lactoferrin. J Immunol 1984, 132:2370-2374.
116. Shau H, Kim A, Golub SH. Modulation of natural killer and lymphokine activated killer cell cytotoxicity by lactoferrin. J Leukoc Biol 1992; 51: 343-349.
117. Furmanski P, He J, Ying L, Bezault J, Bhimani R, Ho K. Functional significance of the binding of lactoferrin to DNA. In: Hutchens TW, Lönnerdal B. (eds) Lactoferrin: Interactions and Biological Functions. Totowa, NJ: Humana, 1997; 313-332.
118. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995; 374; 546-549.
119. Britigan BE, Lewis TS, Waldschmidt M, McCormick ML, Krieg AM. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. J Immunol 2001; 167: 2921-2928.
120. Lima MF, Kierszenbaum F. Lactoferrin effects on phagocytic cell function. I. Increased uptake and killing of an intracellular parasite by murine macrophages and human monocytes. J Immunol 1985; 134: 4176-4183.
121. Lima MF, Kierszenbaum F. Lactoferrin effects of phagocytic cell function. II. The presence of iron is required for the lactoferrin molecule to stimulate intracellular killing by macrophages but not to enhance the uptake of particles and microorganisms. J Immunol 1987; 139: 1647-1652.
122. Richie ER, Hilliard JK, Gilmore R, Gillespi DJ. Human milk-derived lactoferrin inhibits mitogen and alloantigen induced human lymphocyte proliferation. J Reprod Immunol 1987; 12: 137-148.
123. Crouch SPM, Slater KJ, Fletcher J. Regulation of cytokine release from mononuclear cells by the iron-binding protein lactoferrin. Blood 1992; 80: 235-240.
124. Mattsby-Baltzer I, Rosenau A, Motas C, Elverfors J, Engberg I, Hanson LA. Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr Res 1996; 40: 257-262.
125. Machnicki M, Zimecki M, Zagulski T. Lactoferrin regulates the release of tumor necrosis factor alpha and interleukin 6 in vivo. Int J Exp Pathol 1993; 74: 433-439.
126. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14 serves as the cellular receptor for complexes of LPS with LPS binding protein. Science 1990; 249: 1431-1433.
127. Ziegler-Heitbrock HW, Ulevitch RJ. CD14: cell surface receptor and differentiation marker. Immunol Today 1993; 14: 121-125.
128. Frey EA, Miller DS, Jahr TG et al. Soluble CD14 participates in the response of cells to lipopolysaccharide. J Exp Med 1992; 176: 1665-1671.
129. Dentener MA, Bazil V, Von Asmuth EJ, Ceska M, Buurman WA. Involvement of CD14 in lipopolysaccharide-induced tumor necrosis factor-alpha, IL-6 and IL-8 release by human monocytes and alveolar macrophages. J Immunol 1993; 150: 2885-2891.
130. Tobias PS, Tapping RI, Gegner JA. Endotoxin interactions with lipopolysaccharide-responsive cells. Clin Infect Dis 1999; 28: 476-481.
131. Yang RB, Mark MR, Gurney AL, Godowski PJ. Signaling events induced by lipopolysaccharide-activated toll-like receptor 2. J Immunol 1999; 163: 639-643.
132. Tobias PS, Soldau K, Ulevitch RJ. Identification of a lipid A binding site in the acute phase reactant LPS binding protein. J Biol Chem 1989; 264: 10867-10871.
133. Tobias PS, Mathison JC, Ulevitch RJ. A family of LPS-binding proteins involved in responses to Gram-negative sepsis. J Biol Chem 1988; 263: 13479-J3481.
134. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone Jr MA. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Nad Acad Sci USA 1987; 84: 9238-9242.
135. Pugin J, Schurer-Maly CC, Leturcq D, Moriarty A, Ulevitch RJ, Tobias PS. Lipopolysaccharide activation of human endothelial and epithelial cells is mediated by lipopolysaccharide-binding protein and soluble CD14. Proc Natl Acad Sci USA 1993; 90: 2744-2748.
136. Elass-Rochard E, Legrand D, Salmon V et al. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect Immun 1998; 66: 486-491.
137. Baveye S, Elass E, Fernig DG, Blanquart C, Mazurier J, Legrand D. Human lactoferrin interacts with soluble CD14 and inhibits expression of endothelial adhesion molecules, E-selectin and ICAM-1, induced by the CD14-lipopolysaccharide complex. Infect Immun 2000; 68: 6519-6525.
138. Miller RA, Britigan BE. The formation and biologic significance of phagocyte-derived oxidants. J Invest Med 1995; 43: 39-49.
139. Britigan BE, Rosen GM, Thompson BY, Chai Y, Cohen MS. Stimulated human neutrophils limit iron-catalyzed hydroxyl radical formation as detected by spin-trapping techniques. J Biol Chem 1986; 261: 17026-17032.
140. Britigan BE, Serody JS, Hayek MB, Charniga LM, Cohen MS. Uptake of lactoferrin by mononuclear phagocytes inhibits their ability to form hydroxyl radical and protects them from membrane autoperoxidation. J Immunol 1991; 147: 4271-4277.
141. Britigan BE, Lewis TS, Olakanmi O, McCormick ML, Miller RA. The impact of phagocyte-lactoferrin interactions on inflammation. In: Hutchens TW, Lönnerdal B. (eds) Lactoferrin: Interactions and Biological Functions. Totowa, NJ: Humana, 1997; 211-232.
142. Kievits F, Kijlstra A. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin. Immunology 1985; 54: 449-456.
143. Kulics J, Kijlstra A. The effect of lactoferrin on complement mediated modulation of immune complex size. Immunol Lett 1987; 14: 349-353.
144. Elass E, Masson M, Mazurier J, Legrand D. Lactoferrin inhibits the lipopolysaccharide-induced expression and proteoglycan-binding ability of interleukin-8 in human endothelial cells. Infect Immun 2002; 70: 1860-1866.
145. Hipperstiel S, Soeth S, Kellas B et al. Rho proteins and the p38-MAPK pathway are important mediators for LPS-induced interleukin-8 expression in human endothelial cells. Blood 2000; 95: 3044-3051.
146. Schroder JM, Christophers E. Secretion of novel and homologous neutrophil activating peptides by LPS stimulated human endothelial cells. J Immunol 1989; 142: 244-251.
147. Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000; 95: 3032-3043.
148. Bullen JJ, Rogers HJ, Leigh L. Iron-binding proteins in milk and resistance to Escherichia coli infection in infants. BMJ 1972; 1: 69-75.
149. Howie PW, Forsyth JS, Ogston SA, Clark A, Florey CD. Protective effect of breast feeding against infection. BMJ 1990; 300: 11-16.
150. Zagulski T, Lipinski P, Zagulska A, Broniek S, Jarzabek Z. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br J Exp Pathol 1989; 70; 697-704.
151. Teraguchi S, Shin K, Ozawa K et al. Bacteriostatic effect of orally administered bovine lactoferrin on proliferation of Clostridium species in the gut of mice fed bovine milk. Appl Environ Microbiol 1995; 61: 501-506.
152. Teraguchi S, Shin K, Ogata T et al. Orally administered bovine lactoferrin inhibits bacterial translocation in mice fed bovine milk. Appl Environ Microbiol 1995; 61: 4131-4134.
153. Dial EJ, Lichtenberger LM. Effect of lactoferrin on Helicobacter felis induced gastritis. Biochem Cell Biol 2002; 80: 113-117.
154. Opekun AR, El-Zaimaity HM, Osato MS et al. Novel therapies for Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 35-42.
155. Håversen LA, Engberg I, Baltzer L, Dolphin G, Hanson LÅ, Mattsby-Baltzer I. Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice. Infect Immun 2000; 68: 5816-5823.
156. van Deventer SJH, Buller HR, ten Cate JW, Sturk A, Pauw W. Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet 1988; 1: 605-609.
157. Ziegler EJ, Fisher Jr CJ, Srung CL, the HA-1A Sepsis Study Group. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324: 429-436.
158. Lee WJ, Farmer JL, Hilty M, Kim YB. The protective effects of lactoferrin feeding against endotoxin lethal shock in germfree piglets. Infect Immun 1998; 66: 1421-1426.
159. Seifert J, Molkewehrum M, Oesser S, Nebermann L, Schulze C. Endotoxin inactivation by enterally applied colostrum of different composition. Eur Surg Res 2000; 34: 68-72.
160. Guillen C, McInnes IB, Vaughan D, Speekenbrink AB, Brock JH. The effect of local administration of lactoferrin on inflammation in murine autoinumme and infectious arthritis. Arthritis Rheum 2000; 43: 2073-2080.